SinoMab BioScience Limited — Regulatory Filings 2020

Sep 1, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [29 x 43] intentionally omitted <==

==> picture [29 x 43] intentionally omitted <==

SinoMab BioScience Limited 中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

VOLUNTARY ANNOUNCEMENT IND APPROVAL FOR SN1011

Reference is made to the announcements of SinoMab BioScience Limited (中國抗體製藥有限 公司) (the “ Company ”, together with its subsidiaries, the “ Group ”) on 14 November 2019, 29 January 2020 and 29 June 2020 in relation to the latest research and development progress of one of the Group’s key products, SN1011.

The board of directors (the “ Board ”) of the Company is pleased to announce that, on 27 August 2020, the Investigational New Drug (“ IND ”) application of SN1011 for autoimmune disease has been approved by the National Medical Products Administration of China (the “ NMPA ”). The IND approval would enable the Company to conduct comprehensive clinical development programs for the treatment of systemic lupus erythematosus (“ SLE ”) in China. This would be the Company’s first targeted indication of SN1011. The Company plans to initiate the Phase I clinical study in China in the near future.

SN1011 is the Company’s third generation, covalent reversible Bruton’s tyrosine kinase (“ BTK ”) inhibitor designed for higher selectivity and superior efficacy for the long-term treatment of SLE, rheumatoid arthritis, pemphigus, multiple sclerosis and other immunological diseases. SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of selectivity and affinity.

By Order of the Board SinoMab BioScience Limited Dr. Shui On LEUNG Executive Director, Chairman and Chief Executive Director

Hong Kong, 1 September 2020

As at the date of this announcement, the executive directors of the Company are Dr. Shui On LEUNG and Mr. Jing QIANG, the non-executive directors of the Company are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU and Mr. Huiyuan MA, and the independent non-executive directors of the Company are Mr. George William Hunter CAUTHERLEY, Mr. Michael James Connolly HOGAN, Mr. Ping Cho Terence HON and Mr. Dylan Carlo TINKER.